Full Program Just Released!
Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Peng Guo

Peng Guo

Professor & Principal Investigator Hangzhou Institute of Medicine, Chinese Academy of Sciences

Seminars

Monday 12th October 2026

Exploring “ADC + Antibody” as an Emerging Combination Strategy for Solid Tumor Therapies

10:30 am

Explaining rationale for combining a HER2 ADC with trastuzumab
Describing preclinical and clinical results of combination trials, highlighting clinical benefit of ADC antibody combinations
Investigating mechanism to understand how antibody combination helps ADC overcome binding site barrier to improve tumor penetration and improve efficacy

Peng Guo - Speaker at 17th World ADC San Diego Summit

View all Speakers

View Event Brochure